$TDOC
Teladoc Health, Inc. Stock $tdoc

$tdoc Overview Financials Valuation SEC Filings Company Website

2024 Q4 Form 10-Q Financial Statement

#000147744924000225 Filed on October 31, 2024

Income Statement

Concept	2024 Q4	2024 Q3
Revenue		$640.5M
YoY Change		-2.99%
Cost Of Revenue		$179.7M
YoY Change		-3.36%
Gross Profit		$460.8M
YoY Change		-2.85%
Gross Profit Margin		71.94%
Selling, General & Admin		$161.7M
YoY Change		-3.76%
% of Gross Profit		35.1%
Research & Development		$72.38M
YoY Change		-14.13%
% of Gross Profit		15.71%
Depreciation & Amortization		$89.57M
YoY Change		-5.02%
% of Gross Profit		19.44%
Operating Expenses		$234.1M
YoY Change		-7.22%
Operating Profit		-$44.40M
YoY Change		-31.4%
Interest Expense		$5.660M
YoY Change		0.25%
% of Operating Profit
Other Income/Expense, Net		$2.239M
YoY Change		-224.94%
Pretax Income		-$32.50M
YoY Change		-45.44%
Income Tax		$780.0K
% Of Pretax Income
Net Earnings		-$33.28M
YoY Change		-41.7%
Net Earnings / Revenue		-5.2%
Basic Earnings Per Share		-$0.19
Diluted Earnings Per Share		-$0.19
COMMON SHARES
Basic Shares Outstanding	172.2M shares	171.2M shares
Diluted Shares Outstanding		171.5M shares

Balance Sheet

Concept	2024 Q4	2024 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments		$1.244B
YoY Change		20.65%
Cash & Equivalents		$1.244B
Short-Term Investments
Other Short-Term Assets		$983.0K
YoY Change		-88.17%
Inventory		$36.99M
Prepaid Expenses		$68.47M
Receivables		$212.0M
Other Receivables		$11.50M
Total Short-Term Assets		$1.609B
YoY Change		15.97%
LONG-TERM ASSETS
Property, Plant & Equipment		$28.03M
YoY Change		-14.77%
Goodwill		$283.2M
YoY Change		-73.61%
Intangibles		$1.497B
YoY Change		-13.4%
Long-Term Investments
YoY Change
Other Assets		$77.91M
YoY Change		4.65%
Total Long-Term Assets		$1.920B
YoY Change		-34.72%
TOTAL ASSETS
Total Short-Term Assets		$1.609B
Total Long-Term Assets		$1.920B
Total Assets		$3.529B
YoY Change		-18.47%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable		$37.80M
YoY Change		45.4%
Accrued Expenses		$254.5M
YoY Change		13.13%
Deferred Revenue		$88.33M
YoY Change		-10.96%
Short-Term Debt		$0.00
YoY Change
Long-Term Debt Due		$550.7M
YoY Change
Total Short-Term Liabilities		$931.4M
YoY Change		131.32%
LONG-TERM LIABILITIES
Long-Term Debt		$990.6M
YoY Change		-35.59%
Other Long-Term Liabilities		$736.0K
YoY Change		-56.53%
Total Long-Term Liabilities		$736.0K
YoY Change		-56.53%
TOTAL LIABILITIES
Total Short-Term Liabilities		$931.4M
Total Long-Term Liabilities		$736.0K
Total Liabilities		$2.021B
YoY Change		399.81%
SHAREHOLDERS EQUITY
Retained Earnings		-$16.18B
YoY Change		6.46%
Common Stock		$17.73B
YoY Change		1.09%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity		$1.508B
YoY Change
Total Liabilities & Shareholders Equity		$3.529B
YoY Change		-18.47%

Cashflow Statement

Concept	2024 Q4	2024 Q3
OPERATING ACTIVITIES
Net Income		-$33.28M
YoY Change		-41.7%
Depreciation, Depletion And Amortization		$89.57M
YoY Change		-5.02%
Cash From Operating Activities		$110.2M
YoY Change		4.33%
INVESTING ACTIVITIES
Capital Expenditures		$31.15M
YoY Change		-17.16%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities		-$31.15M
YoY Change		-17.16%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities		698.0K
YoY Change		-86.04%
NET CHANGE
Cash From Operating Activities		110.2M
Cash From Investing Activities		-31.15M
Cash From Financing Activities		698.0K
Net Change In Cash		79.73M
YoY Change		9.21%
FREE CASH FLOW
Cash From Operating Activities		$110.2M
Capital Expenditures		$31.15M
Free Cash Flow		$79.03M
YoY Change		16.22%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2024
CY2024Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	37801000	usd
	dei	Document Type DocumentType	10-Q
	dei	Security Exchange Name SecurityExchangeName	NYSE
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	false
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2024Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	172166723	shares
CY2024Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1243866000	usd
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1123675000	usd
CY2024Q3	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	4318000	usd
CY2023Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	4240000	usd
CY2024Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	212039000	usd
CY2023Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	217423000	usd
CY2024Q3	us-gaap	Inventory Net InventoryNet	36993000	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	29513000	usd
CY2024Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	115738000	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	118437000	usd
CY2024Q3	us-gaap	Assets Current AssetsCurrent	1608636000	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	1489048000	usd
CY2024Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	28030000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	32032000	usd
CY2024Q3	us-gaap	Goodwill Goodwill	283190000	usd
CY2023Q4	us-gaap	Goodwill Goodwill	1073190000	usd
CY2024Q3	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	1496698000	usd
CY2023Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	1677781000	usd
CY2024Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	34115000	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	40060000	usd
CY2024Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	77912000	usd
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	80258000	usd
CY2024Q3	us-gaap	Assets Assets	3528581000	usd
CY2024Q3	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	66437000	usd
CY2023Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	102686000	usd
CY2024Q3	us-gaap	Stockholders Equity StockholdersEquity	1507702000	usd
CY2024Q3	us-gaap	Stockholders Equity StockholdersEquity	1507702000	usd
CY2023Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	57973000	usd
CY2023Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-2740000	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-57073000	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	2294050000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	2307745000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1929083000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1941888000	usd
CY2023Q4	tdoc	Cloud Computing Costs Net CloudComputingCostsNet	41100000	usd
CY2023Q3	tdoc	Cloud Computing Expense CloudComputingExpense	600000	usd
	tdoc	Cloud Computing Expense CloudComputingExpense	3700000	usd
	tdoc	Cloud Computing Expense CloudComputingExpense	2400000	usd
CY2023Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	34312000	usd
CY2023Q4	tdoc	Accrued Liabilities And Other Liabilities Excluding Accrued Compensation Current AccruedLiabilitiesAndOtherLiabilitiesExcludingAccruedCompensationCurrent	178634000	usd
CY2024Q3	us-gaap	Convertible Debt ConvertibleDebt	1541274000	usd
CY2023Q4	us-gaap	Convertible Debt ConvertibleDebt	1538688000	usd
CY2024Q3	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://www.teladoc.com/20240930#AccruedLiabilitiesAndOtherLiabilitiesExcludingAccruedCompensationCurrent
CY2023Q4	us-gaap	Assets Assets	4392369000	usd
CY2023Q4	tdoc	Accrued Liabilities And Other Liabilities Excluding Accrued Compensation Current AccruedLiabilitiesAndOtherLiabilitiesExcludingAccruedCompensationCurrent	178634000	usd
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-5212000	usd
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-9761000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-3675000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	696000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-2849000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-14070000	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	8328000	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-18246000	usd
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	18362000	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-5851000	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-21670000	usd
	tdoc	Increase Decrease In Accrued Liabilities And Other Current Liabilities Excluding Accrued Compensation IncreaseDecreaseInAccruedLiabilitiesAndOtherCurrentLiabilitiesExcludingAccruedCompensation	13980000	usd
	tdoc	Increase Decrease In Accrued Liabilities And Other Current Liabilities Excluding Accrued Compensation IncreaseDecreaseInAccruedLiabilitiesAndOtherCurrentLiabilitiesExcludingAccruedCompensation	17075000	usd
	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	-35943000	usd
	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	433000	usd
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-10456000	usd
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-1261000	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-8088000	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-7133000	usd
	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	-336000	usd
	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	75000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	207778000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	219939000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	4658000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	10060000	usd
	us-gaap	Payments For Software PaymentsForSoftware	89750000	usd
	us-gaap	Payments For Software PaymentsForSoftware	109781000	usd
CY2023Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	660238000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1929083000	usd
CY2024Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	640508000	usd
CY2023Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	660238000	usd
CY2023Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	109282000	usd
CY2023Q4	tdoc	Deferred Device Cost And Other DeferredDeviceCostAndOther	50276000	usd
CY2022Q4	us-gaap	Goodwill Impaired Accumulated Impairment Loss GoodwillImpairedAccumulatedImpairmentLoss	12300000000	usd
CY2022Q4	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	2	segment
CY2024Q3	us-gaap	Capitalized Computer Software Amortization1 CapitalizedComputerSoftwareAmortization1	35817000	usd
CY2023Q3	us-gaap	Capitalized Computer Software Amortization1 CapitalizedComputerSoftwareAmortization1	22645000	usd
	us-gaap	Capitalized Computer Software Amortization1 CapitalizedComputerSoftwareAmortization1	97453000	usd
CY2024Q3	tdoc	Accrued Consulting And Customer Service Fees Current AccruedConsultingAndCustomerServiceFeesCurrent	15943000	usd
CY2024Q3	us-gaap	Accrued Insurance Current AccruedInsuranceCurrent	7278000	usd
CY2023Q4	us-gaap	Convertible Debt ConvertibleDebt	1538688000	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	3464000	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	12766000	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	11580000	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	8474000	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	6319000	usd
CY2024Q3	tdoc	Lessee Operating Lease Liability Payments Due Year Five And After Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndAfterYearFive	13451000	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	56054000	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	8450000	usd
CY2024Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	47604000	usd
CY2024Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	10708000	usd
CY2024Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	36896000	usd
	tdoc	Earnings Before Interest Taxes Depreciation And Amortization EarningsBeforeInterestTaxesDepreciationAndAmortization	235876000	usd
	tdoc	Earnings Before Interest Taxes Depreciation And Amortization EarningsBeforeInterestTaxesDepreciationAndAmortization	213677000	usd
	dei	Entity Central Index Key EntityCentralIndexKey	0001477449
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2024-09-30
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	04-3705970
	dei	Entity Address Address Line1 EntityAddressAddressLine1	2 Manhattanville Road
	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 203
CY2024Q3	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	88325000	usd
CY2023Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	95659000	usd
	dei	Entity File Number EntityFileNumber	001-37477
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	43637000	usd
CY2024Q3	tdoc	Accrued Liabilities And Other Liabilities Excluding Accrued Compensation Current AccruedLiabilitiesAndOtherLiabilitiesExcludingAccruedCompensationCurrent	188095000	usd
CY2024Q3	us-gaap	Convertible Debt Current ConvertibleDebtCurrent	550723000	usd
CY2023Q4	us-gaap	Convertible Debt Current ConvertibleDebtCurrent	0	usd
CY2024Q3	us-gaap	Liabilities Current LiabilitiesCurrent	931381000	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	420616000	usd
CY2024Q3	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	736000	usd
CY2023Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	1080000	usd
CY2024Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	36896000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	42837000	usd
CY2024Q3	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	10469000	usd
CY2023Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	13623000	usd
CY2024Q3	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	50846000	usd
CY2023Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	49452000	usd
CY2024Q3	us-gaap	Convertible Debt Noncurrent ConvertibleDebtNoncurrent	990551000	usd
CY2023Q4	us-gaap	Convertible Debt Noncurrent ConvertibleDebtNoncurrent	1538688000	usd
CY2024Q3	us-gaap	Liabilities Liabilities	2020879000	usd
CY2023Q4	us-gaap	Liabilities Liabilities	2066296000	usd
CY2024Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2024Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2024Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2024Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	171944014	shares
CY2024Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	171944014	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	166658253	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	166658253	shares
CY2024Q3	us-gaap	Common Stock Value CommonStockValue	172000	usd
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	167000	usd
CY2024Q3	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	17726127000	usd
CY2023Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	17591551000	usd
CY2024Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-16181491000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-15228655000	usd
CY2024Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-37106000	usd
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-36990000	usd
CY2024Q3	us-gaap	Stockholders Equity StockholdersEquity	1507702000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	2326073000	usd
CY2024Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	3528581000	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	4392369000	usd
CY2024Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	640508000	usd
CY2023Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	660238000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1929083000	usd
CY2024Q3	us-gaap	Cost Of Goods And Service Excluding Depreciation Depletion And Amortization CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization	179745000	usd
CY2023Q3	us-gaap	Cost Of Goods And Service Excluding Depreciation Depletion And Amortization CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization	185960000	usd
	us-gaap	Cost Of Goods And Service Excluding Depreciation Depletion And Amortization CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization	562342000	usd
	us-gaap	Cost Of Goods And Service Excluding Depreciation Depletion And Amortization CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization	566607000	usd
CY2024Q3	us-gaap	Marketing And Advertising Expense MarketingAndAdvertisingExpense	177462000	usd
CY2023Q3	us-gaap	Marketing And Advertising Expense MarketingAndAdvertisingExpense	186152000	usd
	us-gaap	Marketing And Advertising Expense MarketingAndAdvertisingExpense	531061000	usd
	us-gaap	Marketing And Advertising Expense MarketingAndAdvertisingExpense	541698000	usd
CY2024Q3	us-gaap	Selling Expense SellingExpense	47465000	usd
CY2023Q3	us-gaap	Selling Expense SellingExpense	52309000	usd
	us-gaap	Selling Expense SellingExpense	152267000	usd
	us-gaap	Selling Expense SellingExpense	160329000	usd
CY2023Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	84289000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	230522000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	258583000	usd
CY2024Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	114245000	usd
CY2023Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	115716000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	335494000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	355702000	usd
CY2024Q3	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	usd
CY2023Q3	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	usd
	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	790000000	usd
	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	usd
CY2024Q3	us-gaap	Business Combination Acquisition Related Costs BusinessCombinationAcquisitionRelatedCosts	457000	usd
CY2023Q3	us-gaap	Business Combination Acquisition Related Costs BusinessCombinationAcquisitionRelatedCosts	5824000	usd
	us-gaap	Business Combination Acquisition Related Costs BusinessCombinationAcquisitionRelatedCosts	1287000	usd
	us-gaap	Business Combination Acquisition Related Costs BusinessCombinationAcquisitionRelatedCosts	16848000	usd
CY2024Q3	us-gaap	Restructuring Costs RestructuringCosts	3580000	usd
CY2023Q3	us-gaap	Restructuring Costs RestructuringCosts	411000	usd
	us-gaap	Restructuring Costs RestructuringCosts	14753000	usd
	us-gaap	Restructuring Costs RestructuringCosts	16043000	usd
CY2024Q3	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	86906000	usd
CY2023Q3	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	91834000	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	276825000	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	231205000	usd
CY2024Q3	us-gaap	Depreciation Nonproduction DepreciationNonproduction	2666000	usd
CY2023Q3	us-gaap	Depreciation Nonproduction DepreciationNonproduction	2468000	usd
	us-gaap	Depreciation Nonproduction DepreciationNonproduction	7203000	usd
	us-gaap	Depreciation Nonproduction DepreciationNonproduction	8345000	usd
CY2024Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-44401000	usd
CY2023Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-64725000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-972671000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-213472000	usd
CY2024Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	15326000	usd
CY2023Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	12606000	usd
	us-gaap	Investment Income Interest InvestmentIncomeInterest	42840000	usd
	us-gaap	Investment Income Interest InvestmentIncomeInterest	33075000	usd
CY2024Q3	us-gaap	Interest Expense Nonoperating InterestExpenseNonoperating	5660000	usd
	us-gaap	Interest Expense Nonoperating InterestExpenseNonoperating	16957000	usd
	us-gaap	Interest Expense Nonoperating InterestExpenseNonoperating	16744000	usd
CY2024Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	2239000	usd
CY2023Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-1792000	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	1306000	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	2908000	usd
CY2024Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-32496000	usd
CY2023Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-59557000	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-945482000	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-194233000	usd
CY2024Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	780000	usd
CY2023Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-2484000	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	7354000	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-2755000	usd
CY2024Q3	us-gaap	Net Income Loss NetIncomeLoss	-33276000	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-57073000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-952836000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-191478000	usd
CY2024Q3	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	1860000	usd
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-116000	usd
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	1256000	usd
CY2024Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-31416000	usd
CY2023Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-59813000	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-952952000	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-190222000	usd
CY2024Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.19
CY2024Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.19
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.17
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.17
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	1502086000	usd
CY2024Q3	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	34000	usd
CY2024Q3	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	0	usd
	tdoc	Earnings Before Interest Taxes Depreciation And Amortization EarningsBeforeInterestTaxesDepreciationAndAmortization	213677000	usd
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Amendment Flag AmendmentFlag	false
CY2024Q3	us-gaap	Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1 RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1	P3M
CY2024Q3	us-gaap	Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1 RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1	P1Y
CY2023Q4	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://www.teladoc.com/20240930#AccruedLiabilitiesAndOtherLiabilitiesExcludingAccruedCompensationCurrent
CY2024Q3	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://www.teladoc.com/20240930#AccruedLiabilitiesAndOtherLiabilitiesExcludingAccruedCompensationCurrent
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity Registrant Name EntityRegistrantName	TELADOC HEALTH, INC.
	dei	Entity Address City Or Town EntityAddressCityOrTown	Purchase
	dei	Entity Address State Or Province EntityAddressStateOrProvince	NY
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	10577
	dei	City Area Code CityAreaCode	203
	dei	Local Phone Number LocalPhoneNumber	635-2002
	dei	Security12b Title Security12bTitle	Common Stock, par value $0.001 per share
	dei	Trading Symbol TradingSymbol	TDOC
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1941888000	usd
CY2024Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	72383000	usd
CY2024Q3	us-gaap	Costs And Expenses CostsAndExpenses	684909000	usd
CY2023Q3	us-gaap	Costs And Expenses CostsAndExpenses	724963000	usd
	us-gaap	Costs And Expenses CostsAndExpenses	2901754000	usd
	us-gaap	Costs And Expenses CostsAndExpenses	2155360000	usd
CY2023Q3	us-gaap	Interest Expense Nonoperating InterestExpenseNonoperating	5646000	usd
CY2023Q3	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-2740000	usd
CY2023Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.35
CY2023Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.35
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-5.61
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-5.61
CY2024Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	171496282	shares
CY2024Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	171496282	shares
CY2023Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	165119379	shares
CY2023Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	165119379	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	169824993	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	169824993	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	164079194	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	164079194	shares
CY2024Q3	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	0	usd
CY2024Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	36998000	usd
CY2024Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	1860000	usd
CY2024Q3	us-gaap	Net Income Loss NetIncomeLoss	-33276000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	2326073000	usd
	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	2711000	usd
	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	0	usd
	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	3153000	usd
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	128717000	usd
	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-116000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-952836000	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	2295144000	usd
CY2023Q3	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	746000	usd
CY2023Q3	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	0	usd
CY2023Q3	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	0	usd
	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	1423000	usd
	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	0	usd
	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	5790000	usd
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	169314000	usd
	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	1256000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-191478000	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	2294050000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-952836000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-191478000	usd
	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	790000000	usd
	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	276825000	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	231205000	usd
	us-gaap	Depreciation Nonproduction DepreciationNonproduction	7203000	usd
	us-gaap	Depreciation Nonproduction DepreciationNonproduction	8345000	usd
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	7144000	usd
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	8325000	usd
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	2199000	usd
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	4935000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	118479000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	154727000	usd
	us-gaap	Deferred Income Taxes And Tax Credits DeferredIncomeTaxesAndTaxCredits	611000	usd
	us-gaap	Deferred Income Taxes And Tax Credits DeferredIncomeTaxesAndTaxCredits	-6658000	usd
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-1439000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-94408000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-119841000	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	2711000	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	1423000	usd
	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans	3721000	usd
	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans	8597000	usd
	tdoc	Cash Related To Tax Withholding For Share Based Compensation Net CashRelatedToTaxWithholdingForShareBasedCompensationNet	-176000	usd
	tdoc	Cash Related To Tax Withholding For Share Based Compensation Net CashRelatedToTaxWithholdingForShareBasedCompensationNet	2609000	usd
	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	-2000	usd
	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	0	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	6254000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	12629000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	119624000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	112727000	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	567000	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-382000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1123675000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	918182000	usd
CY2024Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1243866000	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1030527000	usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	7234000	usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	6317000	usd
	us-gaap	Interest Paid InterestPaid	8662000	usd
	us-gaap	Interest Paid InterestPaid	8687000	usd
	tdoc	Property And Equipment Net And Intangibles Net Accruals Incurred But Not Yet Paid PropertyAndEquipmentNetAndIntangiblesNetAccrualsIncurredButNotYetPaid	3706000	usd
	tdoc	Property And Equipment Net And Intangibles Net Accruals Incurred But Not Yet Paid PropertyAndEquipmentNetAndIntangiblesNetAccrualsIncurredButNotYetPaid	10050000	usd
	us-gaap	Nature Of Operations NatureOfOperations	Organization and Description of Business<div style="text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Teladoc Health, Inc., together with its subsidiaries, is referred to herein as “Teladoc Health,” or the “Company,” and is the global leader in whole person virtual care, forging a new healthcare experience with better convenience, outcomes, and value. The Company’s mission is to empower all people everywhere to live their healthiest lives by transforming the healthcare experience</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company was incorporated in the State of Texas in June 2002 and changed its state of incorporation to the State of Delaware in October 2008. Effective August 10, 2018, Teladoc, Inc. changed its corporate name to Teladoc Health, Inc. The Company’s principal executive office is located in Purchase, New York.</span></div>
	tdoc	Number Of Professional Associations Consolidated As Variable Interest Entities NumberOfProfessionalAssociationsConsolidatedAsVariableInterestEntities	2	professional_association
	tdoc	Number Of Professional Corporations Consolidated As Variable Interest Entities NumberOfProfessionalCorporationsConsolidatedAsVariableInterestEntities	10	professional_corporation
	us-gaap	Use Of Estimates UseOfEstimates	<div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="padding-left:9pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. The Company bases its estimates on historical experience, current business and economic factors, and various other assumptions that the Company believes are necessary to form a basis for making judgments about the carrying values of assets and liabilities, the recorded amounts of revenue and expenses, and the disclosure of contingent assets and liabilities. The Company is subject to uncertainties such as the impact of future events, economic and political factors, and changes in the Company’s business environment; therefore, actual results could differ from these estimates. Accordingly, the accounting estimates used in the preparation of the Company’s condensed consolidated financial statements will change as new events occur, as more experience is acquired, as additional information is obtained and as the Company’s operating environment evolves. The Company believes that estimates used in the preparation of these condensed consolidated financial statements are reasonable; however, actual results could differ materially from these estimates.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in estimates are made when circumstances warrant. Such changes in estimates and refinements in estimation methodologies are reflected in the Condensed Consolidated Statements of Operations; if material, the effects of changes in estimates are disclosed in the Notes to Unaudited Condensed Consolidated Financial Statements. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Significant estimates and assumptions by management affect areas including the value and useful life of long-lived assets (including intangible assets), the capitalization and amortization of software development costs, allowances for sales, and the accounting for business combinations. Other significant areas include revenue recognition (including performance guarantees), the accounting for income taxes, contingencies, litigation and related legal accruals, the accounting for stock-based compensation awards, and other items as described in Note 2. “Basis of Presentation and Principles of Consolidation" in the Summary of Significant Accounting policies in the 2023 Form 10-K and as may be updated in this Quarterly Report in Note 2. “Basis of Presentation and Principles of Consolidation."</span></div>
	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reclassifications</span></div><div style="padding-left:9pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain prior year amounts have been reclassified to conform to the current year presentation.</span></div>
CY2024Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	640508000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1941888000	usd
CY2022Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	113786000	usd
	tdoc	Contract With Customer Liability Additions ContractWithCustomerLiabilityAdditions	68858000	usd
	tdoc	Contract With Customer Liability Additions ContractWithCustomerLiabilityAdditions	87155000	usd
	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	79346000	usd
	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	88597000	usd
CY2024Q3	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	98794000	usd
CY2023Q3	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	112344000	usd
CY2024Q3	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	60100000	usd
CY2024Q3	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	30100000	usd
CY2024Q3	tdoc	Deferred Device Cost And Other Current DeferredDeviceCostAndOtherCurrent	34781000	usd
CY2023Q4	tdoc	Deferred Device Cost And Other Current DeferredDeviceCostAndOtherCurrent	32703000	usd
CY2024Q3	tdoc	Deferred Device Cost And Other Noncurrent DeferredDeviceCostAndOtherNoncurrent	17414000	usd
CY2023Q4	tdoc	Deferred Device Cost And Other Noncurrent DeferredDeviceCostAndOtherNoncurrent	17573000	usd
CY2024Q3	tdoc	Deferred Device Cost And Other DeferredDeviceCostAndOther	52195000	usd
CY2023Q4	tdoc	Deferred Device Cost And Other DeferredDeviceCostAndOther	50276000	usd
	tdoc	Deferred Device Cost And Other Additions DeferredDeviceCostAndOtherAdditions	28516000	usd
	tdoc	Deferred Device Cost And Other Cost Of Revenue Recognized DeferredDeviceCostAndOtherCostOfRevenueRecognized	26597000	usd
CY2024Q3	tdoc	Deferred Device Cost And Other DeferredDeviceCostAndOther	52195000	usd
CY2024Q3	tdoc	Inventory Raw Materials And Purchased Parts Gross InventoryRawMaterialsAndPurchasedPartsGross	9122000	usd
CY2023Q4	tdoc	Inventory Raw Materials And Purchased Parts Gross InventoryRawMaterialsAndPurchasedPartsGross	9338000	usd
CY2024Q3	us-gaap	Inventory Work In Process InventoryWorkInProcess	804000	usd
CY2023Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	299000	usd
CY2024Q3	us-gaap	Inventory Finished Goods InventoryFinishedGoods	27067000	usd
CY2023Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	19876000	usd
CY2024Q3	us-gaap	Inventory Net InventoryNet	36993000	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	29513000	usd
CY2024Q3	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	68471000	usd
CY2023Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	65651000	usd
CY2024Q3	tdoc	Deferred Device Cost And Other Current DeferredDeviceCostAndOtherCurrent	34781000	usd
CY2023Q4	tdoc	Deferred Device Cost And Other Current DeferredDeviceCostAndOtherCurrent	32703000	usd
CY2024Q3	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	11503000	usd
CY2023Q4	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	12640000	usd
CY2024Q3	us-gaap	Other Assets Current OtherAssetsCurrent	983000	usd
CY2023Q4	us-gaap	Other Assets Current OtherAssetsCurrent	7443000	usd
CY2024Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	115738000	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	118437000	usd
CY2023Q4	us-gaap	Goodwill Goodwill	1073190000	usd
	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	790000000	usd
CY2024Q3	us-gaap	Goodwill Goodwill	283190000	usd
CY2024Q2	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	790000000.0	usd
CY2024Q3	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	usd
CY2024Q3	us-gaap	Goodwill Impaired Accumulated Impairment Loss GoodwillImpairedAccumulatedImpairmentLoss	14200000000	usd
CY2024Q3	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	2681680000	usd
CY2024Q3	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	1184982000	usd
CY2024Q3	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	1496698000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	2584733000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	906952000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	1677781000	usd
	us-gaap	Capitalized Computer Software Amortization1 CapitalizedComputerSoftwareAmortization1	58995000	usd
CY2024Q3	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	86906000	usd
CY2023Q3	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	91834000	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	276825000	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	231205000	usd
CY2024Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear	91312000	usd
CY2024Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	306508000	usd
CY2024Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	248779000	usd
CY2024Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	175334000	usd
CY2024Q3	tdoc	Finite Lived Intangible Asset Expected Amortization Year Four And Thereafter FiniteLivedIntangibleAssetExpectedAmortizationYearFourAndThereafter	674765000	usd
CY2024Q3	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	1496698000	usd
CY2024Q3	tdoc	Cloud Computing Costs Net CloudComputingCostsNet	40400000	usd
CY2024Q3	tdoc	Cloud Computing Expense CloudComputingExpense	1300000	usd
CY2024Q3	tdoc	Accrued Marketing And Advertising Current AccruedMarketingAndAdvertisingCurrent	38826000	usd
CY2023Q4	tdoc	Accrued Marketing And Advertising Current AccruedMarketingAndAdvertisingCurrent	34427000	usd
CY2024Q3	tdoc	Revenue From Contract With Customer Performance Guarantees Current RevenueFromContractWithCustomerPerformanceGuaranteesCurrent	33835000	usd
CY2023Q4	tdoc	Revenue From Contract With Customer Performance Guarantees Current RevenueFromContractWithCustomerPerformanceGuaranteesCurrent	36934000	usd
CY2024Q3	us-gaap	Sales And Excise Tax Payable Current SalesAndExciseTaxPayableCurrent	18492000	usd
CY2023Q4	us-gaap	Sales And Excise Tax Payable Current SalesAndExciseTaxPayableCurrent	12933000	usd
CY2023Q4	tdoc	Accrued Consulting And Customer Service Fees Current AccruedConsultingAndCustomerServiceFeesCurrent	16416000	usd
CY2024Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	10708000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	10752000	usd
CY2024Q3	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	9832000	usd
CY2023Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	9910000	usd
CY2024Q3	tdoc	Accrued Information Technology Expense Current AccruedInformationTechnologyExpenseCurrent	9292000	usd
CY2023Q4	tdoc	Accrued Information Technology Expense Current AccruedInformationTechnologyExpenseCurrent	7605000	usd
CY2023Q4	us-gaap	Accrued Insurance Current AccruedInsuranceCurrent	5777000	usd
CY2024Q3	us-gaap	Interest Payable Current InterestPayableCurrent	5813000	usd
CY2023Q4	us-gaap	Interest Payable Current InterestPayableCurrent	1481000	usd
CY2024Q3	us-gaap	Restructuring Reserve Current RestructuringReserveCurrent	3272000	usd
CY2023Q4	us-gaap	Restructuring Reserve Current RestructuringReserveCurrent	3800000	usd
CY2024Q3	tdoc	Other Current Liabilities Staff Augmentation OtherCurrentLiabilitiesStaffAugmentation	2595000	usd
CY2023Q4	tdoc	Other Current Liabilities Staff Augmentation OtherCurrentLiabilitiesStaffAugmentation	4287000	usd
CY2024Q3	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	32209000	usd
CY2024Q3	tdoc	Accrued Liabilities And Other Liabilities Excluding Accrued Compensation Current AccruedLiabilitiesAndOtherLiabilitiesExcludingAccruedCompensationCurrent	188095000	usd
CY2024Q3	tdoc	Debt Instrument Number Of Series Of Convertible Senior Debt Outstanding DebtInstrumentNumberOfSeriesOfConvertibleSeniorDebtOutstanding	3	debt_series
CY2024Q3	us-gaap	Convertible Debt Current ConvertibleDebtCurrent	550723000	usd
CY2023Q4	us-gaap	Convertible Debt Current ConvertibleDebtCurrent	0	usd
CY2024Q3	us-gaap	Convertible Debt Noncurrent ConvertibleDebtNoncurrent	990551000	usd
CY2023Q4	us-gaap	Convertible Debt Noncurrent ConvertibleDebtNoncurrent	1538688000	usd
CY2024Q3	us-gaap	Convertible Debt ConvertibleDebt	1541274000	usd
CY2024Q3	us-gaap	Restructuring Costs RestructuringCosts	3600000	usd
	us-gaap	Restructuring Costs RestructuringCosts	14800000	usd
CY2023Q3	us-gaap	Restructuring Costs RestructuringCosts	400000	usd
	us-gaap	Restructuring Costs RestructuringCosts	16000000.0	usd
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	12913482	shares
CY2024Q2	tdoc	Share Based Compensation Arrangement By Share Based Payment Award Aggregate Grant Date Target Value ShareBasedCompensationArrangementByShareBasedPaymentAwardAggregateGrantDateTargetValue	15000000.0	usd
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	4182187	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	27.37
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P5Y3M3D
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	13732000	usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	32477	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	20.66
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	253146	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	10.71
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	694000	usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	1006976	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	31.93
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2954542	shares
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	27.13
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P3Y9M
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	1951000	usd
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	2954542	shares
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	27.13
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P3Y9M
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	1951000	usd
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	2493425	shares
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	27.06
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P2Y11M12D
CY2024Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	1951000	usd
CY2024Q3	tdoc	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Total Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodTotalGrantDateFairValue	0.0	usd
CY2023Q3	tdoc	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Total Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodTotalGrantDateFairValue	400000	usd
	tdoc	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Total Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodTotalGrantDateFairValue	400000	usd
	tdoc	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Total Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodTotalGrantDateFairValue	1200000	usd
CY2024Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	34047000	usd
CY2023Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	52945000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	118479000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	154708000	usd
CY2024Q3	us-gaap	Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount	2951000	usd
CY2023Q3	us-gaap	Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount	5028000	usd
	us-gaap	Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount	10238000	usd
	us-gaap	Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount	14606000	usd
CY2024Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1 SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1	36998000	usd
CY2023Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1 SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1	57973000	usd
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1 SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1	128717000	usd
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1 SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1	169314000	usd
CY2024Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	800000	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	7400000	usd
CY2023Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-2500000	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-2800000	usd
	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	2	segment
CY2024Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	640508000	usd
CY2023Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	660238000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1929083000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1941888000	usd
CY2024Q3	tdoc	Earnings Before Interest Taxes Depreciation And Amortization EarningsBeforeInterestTaxesDepreciationAndAmortization	83255000	usd
CY2023Q3	tdoc	Earnings Before Interest Taxes Depreciation And Amortization EarningsBeforeInterestTaxesDepreciationAndAmortization	88757000	usd
CY2024Q3	tdoc	Earnings Before Interest Taxes Depreciation And Amortization EarningsBeforeInterestTaxesDepreciationAndAmortization	83255000	usd
CY2023Q3	tdoc	Earnings Before Interest Taxes Depreciation And Amortization EarningsBeforeInterestTaxesDepreciationAndAmortization	88757000	usd
	tdoc	Earnings Before Interest Taxes Depreciation And Amortization EarningsBeforeInterestTaxesDepreciationAndAmortization	235876000	usd
CY2024Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	34047000	usd
CY2023Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	52945000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	118479000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	154708000	usd
CY2024Q3	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	usd
CY2023Q3	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	usd
	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	790000000	usd
	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	usd
CY2024Q3	us-gaap	Business Combination Acquisition Related Costs BusinessCombinationAcquisitionRelatedCosts	457000	usd
CY2023Q3	us-gaap	Business Combination Acquisition Related Costs BusinessCombinationAcquisitionRelatedCosts	5824000	usd
	us-gaap	Business Combination Acquisition Related Costs BusinessCombinationAcquisitionRelatedCosts	1287000	usd
	us-gaap	Business Combination Acquisition Related Costs BusinessCombinationAcquisitionRelatedCosts	16848000	usd
CY2024Q3	us-gaap	Restructuring Costs RestructuringCosts	3580000	usd
CY2023Q3	us-gaap	Restructuring Costs RestructuringCosts	411000	usd
	us-gaap	Restructuring Costs RestructuringCosts	14753000	usd
	us-gaap	Restructuring Costs RestructuringCosts	16043000	usd
CY2024Q3	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	86906000	usd
CY2023Q3	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	91834000	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	276825000	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	231205000	usd
CY2024Q3	us-gaap	Depreciation Nonproduction DepreciationNonproduction	2666000	usd
CY2023Q3	us-gaap	Depreciation Nonproduction DepreciationNonproduction	2468000	usd
	us-gaap	Depreciation Nonproduction DepreciationNonproduction	7203000	usd
	us-gaap	Depreciation Nonproduction DepreciationNonproduction	8345000	usd
CY2024Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	15326000	usd
CY2023Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	12606000	usd
	us-gaap	Investment Income Interest InvestmentIncomeInterest	42840000	usd
	us-gaap	Investment Income Interest InvestmentIncomeInterest	33075000	usd
CY2024Q3	us-gaap	Interest Expense InterestExpense	5660000	usd
CY2023Q3	us-gaap	Interest Expense InterestExpense	5646000	usd
	us-gaap	Interest Expense InterestExpense	16957000	usd
	us-gaap	Interest Expense InterestExpense	16744000	usd
CY2024Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	2239000	usd
CY2023Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-1792000	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	1306000	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	2908000	usd
CY2024Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-32496000	usd
CY2023Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-59557000	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-945482000	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-194233000	usd
CY2024Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	780000	usd
CY2023Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-2484000	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	7354000	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-2755000	usd
CY2024Q3	us-gaap	Net Income Loss NetIncomeLoss	-33276000	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-57073000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-952836000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-191478000	usd
CY2024Q3	us-gaap	Noncurrent Assets NoncurrentAssets	28030000	usd
CY2023Q4	us-gaap	Noncurrent Assets NoncurrentAssets	32032000	usd
CY2024Q3	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
CY2024Q3	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2024Q3	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false

Files In Submission

Name	View Source	Status
0001477449-24-000225-index-headers.html	Edgar Link	pending
0001477449-24-000225-index.html	Edgar Link	pending
0001477449-24-000225.txt	Edgar Link	pending
0001477449-24-000225-xbrl.zip	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
tdoc-20240930.htm	Edgar Link	pending
tdoc-20240930.xsd	Edgar Link	pending
tdoc-20240930xexx101.htm	Edgar Link	pending
tdoc-20240930xexx311.htm	Edgar Link	pending
tdoc-20240930xexx312.htm	Edgar Link	pending
tdoc-20240930xexx321.htm	Edgar Link	pending
tdoc-20240930xexx322.htm	Edgar Link	pending
tdoc-20240930_cal.xml	Edgar Link	unprocessable
tdoc-20240930_def.xml	Edgar Link	unprocessable
tdoc-20240930_lab.xml	Edgar Link	unprocessable
tdoc-20240930_pre.xml	Edgar Link	unprocessable
tdoc-20240930_htm.xml	Edgar Link	completed
FilingSummary.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$TDOC
Teladoc Health, Inc. Stock $tdoc

2024 Q4 Form 10-Q Financial Statement

#000147744924000225 Filed on October 31, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$TDOC Teladoc Health, Inc. Stock $tdoc

2024 Q4 Form 10-Q Financial Statement

#000147744924000225 Filed on October 31, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$TDOC
Teladoc Health, Inc. Stock $tdoc